Demand for human leukocyte antigen or human platelet antigen-selected platelets: An observational study at Canadian Blood Services.

ABSTRACT:

Background

Platelet transfusion refractoriness (PTR) is a clinically important condition. The Human Leukocyte Antigen and Human Platelet Antigen (HLA/HPA) Platelet Program at Canadian Blood Services (CBS) provides platelet products to support such patients. This study provides a blood operator perspective on the provision of products for the management of immune-mediated PTR (iPTR), including the evaluation of patient data to determine trends in the prevalence and diagnoses associated with iPTR.

Study design and methods

A retrospective observational study of patients enrolled in the CBS HLA/HPA Platelet Program between April 2021 and March 2025. Patient demographics and platelet product issuance were extracted from internal electronic records. Descriptive statistics were uti

SUBMITTER: Rickards N 

PROVIDER: S-EPMC12857877 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature